Scpharmaceuticals (NASDAQ:SCPH) Downgraded by Zacks Investment Research to “Hold”

Scpharmaceuticals (NASDAQ:SCPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “

Separately, ValuEngine cut Scpharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th.



NASDAQ:SCPH traded down $0.09 during trading hours on Wednesday, hitting $5.20. The company had a trading volume of 903 shares, compared to its average volume of 60,308. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.10. The company has a 50-day moving average of $6.33 and a 200 day moving average of $4.42. The company has a market cap of $98.29 million, a P/E ratio of -3.27 and a beta of 0.82. Scpharmaceuticals has a 1 year low of $2.44 and a 1 year high of $7.85.

Scpharmaceuticals (NASDAQ:SCPH) last issued its earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.10. On average, analysts forecast that Scpharmaceuticals will post -1.86 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SCPH. SG Americas Securities LLC purchased a new position in shares of Scpharmaceuticals during the 1st quarter worth $51,000. Alambic Investment Management L.P. purchased a new position in shares of Scpharmaceuticals during the 2nd quarter worth $191,000. Eversept Partners LP purchased a new position in shares of Scpharmaceuticals during the 2nd quarter worth $556,000. Jacobs Levy Equity Management Inc. grew its holdings in shares of Scpharmaceuticals by 55.8% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock worth $118,000 after purchasing an additional 13,225 shares during the period. Finally, Paloma Partners Management Co purchased a new position in shares of Scpharmaceuticals during the 2nd quarter worth $96,000. Institutional investors and hedge funds own 39.67% of the company’s stock.

Scpharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

Featured Story: Should you buy a closed-end mutual fund?

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.